Table 1.
Group | Disease incidence/total (%) | Number of deaths | Disease onset (days)a | Mean clinical scores | ||||
---|---|---|---|---|---|---|---|---|
Day 15b | Day 20c | Day 25c | Day 30c | Day 9–30d | ||||
WT/EAE | 10/10 (100) | 2 | 11.8 ± 0.36 | 2.1 ± 0.38 | 3.1 ± 0.46 | 3.0 ± 0.45 | 3.1 ± 0.48 | 2.34 ± 0.23 |
WT/EAE + GLIB | 10/10 (100) | 1 | 12.9 ± 0.50 | 1.3 ± 0.34 | 1.0 ± 0.34 | 1.0 ± 0.33 | 1.1 ± 0.35 | 0.94 ± 0.08 |
Abcc8−/−/EAE | 10/10 (100) | 0 | 13.0 ± 0.41 | 1.8 ± 0.36 | 1.4 ± 0.31 | 1.3 ± 0.26 | 1.0 ± 0.29 | 1.16 ± 0.12 |
Values are presented as mean ± SEM (10 mice per group)
aDisease onset is defined as the first day of a clinical score of one or more. There was no statistically significant difference in day of onset of disease between the groups
bThere was no statistically significant difference in scores between the groups on day 15
cOn day 20, 25, and 30, the mean clinical scores of mice were significantly lower in WT/EAE + GLIB and Abcc8−/−/EAE groups compared to WT/EAE group. (For all three time points: WT/EAE vs. WT/EAE + GLIB, P < 0.01; WT/EAE vs. Abcc8−/−/EAE, P < 0.01; N = 10; one-way ANOVA with Fisher’s post-hoc comparisons)
dOverall Mean score during the disease phase (Day 9 to 30) is significantly lower in WT/EAE + GLIB and Abcc8−/−/EAE groups compared to WT/EAE group. (WT/EAE vs. WT/EAE + GLIB, P < 0.001; WT/EAE vs. Abcc8−/−/EAE, P < 0.001; N = 10; one-way ANOVA with Fisher’s post-hoc comparisons)